RT Journal Article
T1 Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
A1 Alonso-Álvarez, Sara
A1 Magnano, Laura
A1 Alcoceba, Miguel
A1 Andrade-Campos, Marcio
A1 Espinosa-Lara, Natalia
A1 Rodríguez, Guillermo
A1 Mercadal, Santiago
A1 Carro, Itziar
A1 Sancho, Juan M
A1 Moreno, Miriam
A1 Salar, Antonio
A1 García-Pallarols, Francesc
A1 Arranz, Reyes
A1 Cannata, Jimena
A1 Terol, María José
A1 Teruel, Ana I
A1 Rodríguez, Antonia
A1 Jiménez-Ubieto, Ana
A1 González de Villambrosia, Sonia
A1 Bello, José L
A1 López, Lourdes
A1 Monsalvo, Silvia
A1 Novelli, Silvana
A1 de Cabo, Erik
A1 Infante, María S
A1 Pardal, Emilia
A1 García-Álvarez, María
A1 Delgado, Julio
A1 González, Marcos
A1 Martín, Alejandro
A1 López-Guillermo, Armando
A1 Caballero, María D
K1 cumulative incidence
K1 follicular lymphoma
K1 transformation
AB The diagnostic criteria for follicular lymphoma (FL) transformation vary among the largest series, which commonly exclude histologically-documented transformation (HT) mandatorily. The aims of this retrospective observational multicentre study by the Spanish Grupo Español de Linfoma y Transplante Autólogo de Médula Ósea, which recruited 1734 patients (800 males/934 females; median age 59 years), diagnosed with FL grades 1-3A, were, (i) the cumulative incidence of HT (CI-HT); (ii) risk factors associated with HT; and (iii) the role of treatment and response on survival following transformation (SFT). With a median follow-up of 6·2 years, 106 patients developed HT. Ten-year CI-HT was 8%. Considering these 106 patients who developed HT, median time to transformation was 2·5 years. High-risk FL International Prognostic Index [Hazard ratio (HR) 2·6, 95% confidence interval (CI): 1·5-4·5] and non-response to first-line therapy (HR 2·9, 95% CI: 1·3-6·8) were associated with HT. Seventy out of the 106 patients died (5-year SFT, 26%). Response to HT first-line therapy (HR 5·3, 95% CI: 2·4-12·0), autologous stem cell transplantation (HR 3·9, 95% CI: 1·5-10·1), and revised International Prognostic Index (HR 2·2, 95% CI: 1·1-4·2) were significantly associated with SFT. Response to treatment and HT were the variables most significantly associated with survival in the rituximab era. Better therapies are needed to improve response. Inclusion of HT in clinical trials with new agents is mandatory.
YR 2017
FD 2017-08-07
LK http://hdl.handle.net/10668/11483
UL http://hdl.handle.net/10668/11483
LA en
DS RISalud
RD Apr 9, 2025